X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (169) 169
oncology (138) 138
male (126) 126
female (120) 120
index medicus (115) 115
middle aged (114) 114
aged (108) 108
adult (94) 94
lung neoplasms - drug therapy (77) 77
chemotherapy (61) 61
carcinoma, non-small-cell lung - drug therapy (52) 52
cancer (49) 49
lung cancer (48) 48
lung neoplasms - pathology (47) 47
treatment outcome (45) 45
antineoplastic combined chemotherapy protocols - therapeutic use (43) 43
pharmacology & pharmacy (38) 38
animals (37) 37
japan (32) 32
antineoplastic agents - therapeutic use (29) 29
medicine & public health (29) 29
tumors (29) 29
aged, 80 and over (28) 28
analysis (28) 28
lung cancer, non-small cell (28) 28
pharmacology/toxicology (28) 28
biochemistry & molecular biology (27) 27
lung neoplasms - genetics (26) 26
neoplasms - drug therapy (26) 26
non-small cell lung cancer (26) 26
respiratory system (26) 26
retrospective studies (26) 26
trial (26) 26
cisplatin (25) 25
cancer research (24) 24
dose-response relationship, drug (24) 24
neoplasm staging (24) 24
antineoplastic combined chemotherapy protocols - adverse effects (23) 23
carcinoma, non-small-cell lung - pathology (23) 23
care and treatment (23) 23
medical research (23) 23
amino acid sequence (22) 22
antineoplastic agents - adverse effects (22) 22
cisplatin - administration & dosage (22) 22
expression (22) 22
hematology, oncology and palliative medicine (22) 22
paclitaxel (22) 22
therapy (22) 22
pharmacokinetics (21) 21
carboplatin (20) 20
drug administration schedule (20) 20
lung neoplasms - mortality (19) 19
medicine, experimental (19) 19
mice (19) 19
lung neoplasms - metabolism (18) 18
molecular sequence data (18) 18
paclitaxel - administration & dosage (18) 18
carcinoma, non-small-cell lung - mortality (17) 17
peptides (17) 17
disease-free survival (16) 16
gefitinib (16) 16
original (16) 16
safety (16) 16
adenocarcinoma - drug therapy (15) 15
asian continental ancestry group (15) 15
carboplatin - administration & dosage (15) 15
docetaxel (15) 15
lung neoplasms - therapy (15) 15
phase-iii (15) 15
protein kinase inhibitors - therapeutic use (15) 15
research (15) 15
survival (15) 15
toxicity (15) 15
antimitotic agents (14) 14
antineoplastic agents (14) 14
clinical trials (14) 14
mutation (14) 14
pharmacology (14) 14
prognosis (14) 14
carcinoma, non-small-cell lung - genetics (13) 13
combination (13) 13
metastasis (13) 13
survival rate (13) 13
adenocarcinoma (12) 12
antineoplastic agents - administration & dosage (12) 12
cisplatin - adverse effects (12) 12
erlotinib (12) 12
maximum tolerated dose (12) 12
neoplasms - pathology (12) 12
open-label (12) 12
protein kinase inhibitors - adverse effects (12) 12
pulmonary/respiratory (12) 12
solid tumors (12) 12
studies (12) 12
survival analysis (12) 12
tyrosine kinase inhibitor (12) 12
antibodies, monoclonal - therapeutic use (11) 11
antineoplastic agents - pharmacokinetics (11) 11
carcinoma (11) 11
carcinoma, non-small-cell lung - therapy (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
by Seow, Wei Jie and Matsuo, Keitaro and Hsiung, Chao Agnes and Shiraishi, Kouya and Song, Minsun and Kim, Hee Nam and Wong, Maria Pik and Hong, Yun-Chul and Hosgood, H. Dean and Wang, Zhaoming and Chang, I-Shou and Wang, Jiu-Cun and Chatterjee, Nilanjan and Tucker, Margaret and Wei, Hu and Mitsudomi, Tetsuya and Zheng, Wei and Kim, Jin Hee and Zhou, Baosen and Caporaso, Neil E and Albanes, Demetrius and Shin, Min-Ho and Chung, Lap Ping and An, She-Juan and Wang, Ping and Zheng, Hong and Yatabe, Yasushi and Zhang, Xu-Chao and Kim, Young Tae and Shu, Xiao Ou and Kim, Young-Chul and Bassig, Bryan A and Chang, Jiang and Ho, James Chung Man and Ji, Bu Tian and Kubo, Michiaki and Daigo, Yataro and Ito, Hidemi and Momozawa, Yukihide and Ashikawa, Kyota and Kamatani, Yoichiro and Honda, Takayuki and Sakamoto, Hiromi and Kunitoh, Hideo and Tsuta, Koji and Watanabe, Shun-Ichi and Nokihara, Hiroshi and Miyagi, Yohei and Nakayama, Haruhiko and Matsumoto, Shingo and Tsuboi, Masahiro and Goto, Koichi and Yin, Zhihua and Shi, Jianxin and Takahashi, Atsushi and Goto, Akiteru and Minamiya, Yoshihiro and Shimizu, Kimihiro and Tanaka, Kazumi and Wu, Tangchun and Wei, Fusheng and Wong, Jason Y Y and Matsuda, Fumihiko and Su, Jian and Kim, Yeul Hong and Oh, In-Jae and Song, Fengju and Lee, Victor Ho Fun and Su, Wu-Chou and Chen, Yuh-Min and Chang, Gee-Chen and Chen, Kuan-Yu and Huang, Ming-Shyan and Yang, Pan-Chyr and Lin, Hsien-Chih and Xiang, Yong-Bing and Seow, Adeline and Park, Jae Yong and Kweon, Sun-Seog and Chen, Chien-Jen and Li, Haixin and Gao, Yu Tang and Wu, Chen and Qian, Biyun and Lu, Daru and Liu, Jianjun and Jeon, Hyo-Sung and Hsiao, Chin-Fu and Sung, Jae Sook and Tsai, Ying-Huang and Jung, Yoo Jin and Guo, Huan and Hu, Zhibin and Wang, Wen-Chang and Chung, Charles C and Lawrence, Charles and Burdett, Laurie and Yeager, Meredith and Jacobs, Kevin B and Hutchinson, Amy and ...
Human Molecular Genetics, ISSN 0964-6906, 01/2017, Volume 26, Issue 2, pp. 454 - 465
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 663 - 671
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2014, Volume 20, Issue 12, pp. 3087 - 3093
Journal Article
Annals of Oncology, ISSN 0923-7534, 2016, Volume 27, Issue 12, pp. 2242 - 2250
Journal Article
by Ou, S. I and Camidge, D. R and Engelman, J and Clark, J and Tye, L and Wilner, K and Stephenson, P and Varella-Garcia, M and Iafrate, A and Shaw, A. T and Hainaut, P and Ma, X and Lacas, B and Tsao, M and Douillard, J and Rousseau, V and Dunant, A and Seymour, L and Filipits, M and Graziano, S and He, J and Yang, H and Deng, Q and He, P and Jiang, J and Zhao, M and Gu, X and Zheng, L and Pang, H and Zhou, J. X and Reinmuth, N and Scherer, S. J and Penzel, R and Schnabel, P and Meister, M and Kiemle-Kallee, J and Reuss, A and Fischer, J. R and Wolf, M and Thomas, M and von Laffert, M and Berg, E and Lenze, D and Lohneis, P and Hummel, M and Dietel, M and Han, X and Ma, L and Liu, Y and Zhang, N. N and Li, D and Shi, Y and Furugaki, K and Iwai, T and Moriya, Y and Fujimoto-Ouchi, K and Mok, T. S. K and Park, K and Geater, S. L and Agarwal, S and Han, M and Credi, M and McKee, K and Kuriyama, N and Slichenmyer, W and Tan, E. H and Greillier, L and Martel-Lafay, I and Arpin, D and Pourel, N and Chabaud, S and Lamy, R and Madroszyk, A and Fournel, P and Strom, H. H and Sundstrom, S and Helbekkmo, N and Bremnes, R and Aasebo, U and van Elmpt, W and Ollers, M and Dingemans, A. C and Lambin, P and De Ruysscher, D and Topkan, E and Parlak, C and Topuk, S and Ozyilkan, O and Uyterlinde, W and Vincent, A. D and Belderbos, J and Korse, T and Baas, P and van den Heuvel, M and Satouchi, M and Chiba, Y and Yamamoto, N and Nishimura, Y and Tsujino, K and Fujisaka, Y and ... and on behalf of The Mar-LC Collaborative Group
Annals of Oncology, ISSN 0923-7534, 09/2012, Volume 23, Issue suppl 9, pp. ix389 - ix399
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | ANAPLASTIC LYMPHOMA KINASE | MEDICINE, GENERAL & INTERNAL | SAFETY | CH5424802 | AF-001JP | ADVANCED NSCLC | INHIBITORS | CHEMOTHERAPY | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Medical services | Metastasis | Kinases | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Crizotinib | Treatment outcome | Chemotherapy | Usage | Care and treatment | Lung cancer | Analysis | Dosage and administration | Comparative analysis | Risk factors | Cancer | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
by Felip, E and Carcereny, E and Barlesi, F and Gandhi, L and Sequist, L. V and Kim, S.-W and Groen, H. J. M and Besse, B and Kim, D.-W and Smit, E and Akimov, M and Avsar, E and Bailey, S and Ofosu-Appiah, W and Garon, E. B and Gettinger, S and Weiss, G. J and Salgia, R and Bazhenova, L and Narasimhan, N. I and Dorer, D. J and Rivera, V. M and Zhang, J and Clackson, T and Haluska, F and Shaw, A. T and Camidge, D. R and Sharma, S and Tan, D. S. W and Kim, D and De Pas, T and Vansteenkiste, J. F and Santoro, A and Liu, G and Goldwasser, M and Dai, D and Boral, A. L and Mehra, R and Nishio, M and Kiura, K and Nakagawa, K and Seto, T and Inoue, A and Maemondo, M and Hida, T and Harada, M and Yoshioka, H and Tamura, T and Munster, P and van der Noll, R and Voest, E and Specht, J and Werner, T. L and Dees, E. C and Tan, A. R and Daud, A and Schellens, J and Lolkema, M. P and Griffin, M and Agarwal, N and Falchook, G. S and Kleha, J. F and Durante, M and Smith, D. A and Adams, L and Greshock, J and Morris, S. R and Kurzrock, R and Elez, E and Tabernero, J and Prudkin, L and Agarwal, S and Han, M and Credi, M and Yin, W and Kuriyama, N and Baselga, J and Hong, D. S and Amin, H. M and Fu, S and Piha-Paul, S. A and Klevesath, M. B and Jego, V and Johne, A and Stinchi, S and Cohen, E. E. W and Elisei, R and Schlumberger, M. J and Muller, S. P and Schoffski, P and Brose, M and Shah, M and Miles, D. R and Nguyen, L. T and Sherman, S and Soria, J and Hollebecque, A and Massard, C and Deutsch, E and Varga, A and ...
Annals of Oncology, ISSN 0923-7534, 09/2012, Volume 23, Issue suppl 9, pp. ix152 - ix174
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2014, Volume 25, Issue suppl_4, pp. iv531 - iv531
Abstract Aim: The aim of this trial was to evaluate the safety and efficacy of oral hydration as a substitute for intravenous (IV) hydration after CDDP... 
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2014, Volume 25, Issue suppl_4, pp. iv466 - iv466
Abstract Aim: ONO-4538 (BMS-936558, nivolumab) is a fully human monoclonal antibody targeting PD-1 (programmed cell death 1) and enhances antitumor activity by... 
Journal Article
Cancer Science, ISSN 1347-9032, 05/2017, Volume 108, Issue 5, pp. 1000 - 1006
Journal Article
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 9, pp. 2241 - 2247
Background: Eribulin is a microtubule dynamics inhibitor with a novel mechanism of action. This phase 3 study aimed to compare overall survival (OS) in... 
Phase 3 | Chemotherapy | Eribulin | Non-small cell lung cancer | non-small cell lung cancer | phase 3 | TRIAL | ONCOLOGY | MESYLATE E7389 | eribulin | TAXANE | chemotherapy | DOCETAXEL | ERLOTINIB
Journal Article